Merck KGaA (MKGAF)

158,75 -3,63 (-2,24%) Börsenschluss: 03:54PM EDT

Merck KGaA

Frankfurter Strasse 250
Darmstadt 64293
Germany
49 6151 72 0
https://www.emdgroup.com

Sektor(en): Healthcare
Branche: Drug Manufacturers - Specialty & Generic
Vollzeitmitarbeiter: 62.908

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Ms. Belen Garijo Lopez M.D.	Chair of Executive Board & CEO	7,03M	N/A	1960
Ms. Helene von Roeder	CFO & Member of Executive Board	1,31M	N/A	1970
Dr. Kai Beckmann	CEO of Electronics & Member of the Executive Board	5,15M	N/A	1965
Mr. Peter Guenter	CEO of Healthcare Business & Member of Executive Board	5,93M	N/A	1962
Dr. Matthias J. Heinzel	CEO of Life Science Sector & Member of Executive Board	5,55M	N/A	1967
Ms. Barbara Weiland	Chief Compliance Officer	N/A	N/A	1974
Mr. Dietmar Eidens	Head of the Global HR Business Partner Organization	N/A	N/A	1958
Mr. Frank Gotthardt	Head of Corporate & Government Relations - Europe	N/A	N/A	N/A
Mr. Marc Horn	Head of Life Science Controlling	N/A	N/A	1975
Dr. Michael Heckmeier	Head of the Display Materials Business Unit for Performance Materials	N/A	N/A	1967

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company's Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector. This segment provides drug manufacturers with process development expertise and technologies, such as continuous bioprocessing; testing kits and services; reagents and services; testing solutions that analyze air, water, and soil; and testing and tools, as well as products that help test nutritional value and identify quality inconsistencies. Its Healthcare segment discovers, develops, manufacturers, and markets prescription drugs and biopharmaceuticals for the treatment of oncology, neurology and immunology, fertility, endocrinology, as well as cardiovascular, diabetes, thyroid disorders, and multiple sclerosis; general medicines; and injection device and disease monitoring software. The Electronics segment supplies materials for the semiconductor and display industries and surface design, such as delivery systems and services, as well as surface solutions, including cosmetics, effect pigments, and functional solutions. In addition, it has in-licensing agreement with Debiopharm International SA for developing and commercializing drug candidates for the treatment of head and neck cancer; Jiangsu Hengrui Pharmaceuticals Co. Ltd. for developing, manufacturing, and commercializing drug candidates for the treatment of metastatic colorectal cancer; and Abbisko Therapeutics Co. Ltd. for developing and commercializing of drug candidates for the treatment of tenosynovial giant cell tumor, as well as license and collaboration agreement with Merck KGaA to discover two targeted protein degraders against critical oncogenic proteins. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA operates as a subsidiary of E. Merck KGaA.

Corporate Governance

Merck KGaAs ISS Governance QualityScore, Stand 1. April 2024, lautet 3. Die grundlegenden Scores sind Audit: 1, Vorstand: 4, Shareholderrechte: 10, Kompensation: 2.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.